MorphoSys Initiates Program Against Drug-Resistant MRSA Infections
MorphoSys Secures Access to Innovative Targets through In-licensing and Collaboration Agreement with Absynth Biologics
03-Sep-2010 -
MorphoSys AG announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus ...
antibodies
infectious diseases
inflammation
+3